Understanding Myocardial Metabolism in the Context of Cardio-Oncology.
Understanding Myocardial Metabolism in the Context of Cardio-Oncology.
复制标题
DOI：
10.1016/j.hfc.2022.02.004
复制
发表时间：
2022-07
影响因子：
3.4
通讯作者：
Jing Liu;Zsu-Zsu Chen-Zsu;Jagvi R. Patel;Aarti H Asnani
中科院分区：
文献类型：
--
作者：
Jing Liu;Zsu-Zsu Chen-Zsu;Jagvi R. Patel;Aarti H Asnani
心血管事件，从心律失常到失代偿性心力衰竭，在癌症治疗期间和之后很常见。心血管并发症可能危及生命，从肿瘤学家的角度来看，可能会限制一线癌症治疗的使用。此外，人口老龄化增加了接受癌症治疗的患者的合并症和医疗复杂性的风险。许多人在开始这些治疗之前已经确定了心血管诊断或风险因素。因此，有必要了解导致癌症患者心血管事件的分子机制，并确定可能预防和治疗这两种疾病的新治疗靶点。这篇综述将讨论癌症与心脏之间的代谢相互作用，并将重点介绍Elsevier出版的© 2022的当前策略。本手稿在Elsevier用户许可证https：//www下提供。爱思唯尔。com/open-access/userlicense/1.0/
Cardiovascular events, ranging from arrhythmias to decompensated heart failure, are common during and after cancer therapy. Cardiovascular complications can be lifethreatening, and from the oncologist’s perspective, could limit the use of first-line cancer therapeutics. Moreover, an aging population increases the risk for comorbidities and medical complexity among patients who undergo cancer therapy. Many have established cardiovascular diagnoses or risk factors prior to starting these therapies. Therefore, it is essential to understand the molecular mechanisms that drive cardiovascular events in patients with cancer, and to identify new therapeutic targets that may prevent and treat these two diseases. This review will discuss the metabolic interaction between cancer and the heart and will highlight current strategies of© 2022 published by Elsevier. This manuscript is made available under the Elsevier user license https://www. elsevier. com/open-access/userlicense/1.0/